United States US: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 10.790 % in 2017. United States US: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 10.790 % from Dec 2017 (Median) to 2017, with 1 observations. United States US: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes.; ; International Diabetes Federation, Diabetes Atlas.; Weighted average;

Population-based county-level estimates for diagnosed (DDP), undiagnosed (UDP), and total diabetes prevalence (TDP) were acquired from the Institute for Health Metrics and Evaluation (IHME) for the years 2004-2012 (Evaluation 2017). Prevalence estimates were calculated using a two-stage approach. The first stage used National Health and Nutrition Examination Survey (NHANES) data to predict high fasting plasma glucose (FPG) levels (≥126 mg/dL) and/or hemoglobin A1C (HbA1C) levels (≥6.5% [48 mmol/mol]) based on self-reported demographic and behavioral characteristics (Dwyer-Lindgren, Mackenbach et al. 2016). This model was then applied to Behavioral Risk Factor Surveillance System (BRFSS) data to impute high FPG and/or A1C status for each BRFSS respondent (Dwyer-Lindgren, Mackenbach et al. 2016). The second stage used the imputed BRFSS data to fit a series of small area models, which were used to predict the county-level prevalence of each of the diabetes-related outcomes (Dwyer-Lindgren, Mackenbach et al. 2016). Diagnosed diabetes was defined as the proportion of adults (age 20+ years) who reported a previous diabetes diagnosis, represented as an age-standardized prevalence percentage. Undiagnosed diabetes was defined as proportion of adults (age 20+ years) who have a high FPG or HbA1C but did not report a previous diagnosis of diabetes. Total diabetes was defined as the proportion of adults (age 20+ years) who reported a previous diabetes diagnosis and/or had a high FPG/HbA1C. The age-standardized diabetes prevalence (%) was used as the outcome. The EQI was constructed for 2000-2005 for all US counties and is composed of five domains (air, water, built, land, and sociodemographic), each composed of variables to represent the environmental quality of that _domain. Domain-specific EQIs were developed using principal components analysis (PCA) to reduce these variables within each _domain while the overall EQI was constructed from a second PCA from these individual domains (L. C. Messer et al., 2014). To account for differences in environment across rural and urban counties, the overall and _domain-specific EQIs were stratified by rural urban continuum codes (RUCCs) (U.S. Department of Agriculture, 2015). This dataset is not publicly accessible because: EPA cannot release personally identifiable information regarding living individuals, according to the Privacy Act and the Freedom of Information Act (FOIA). This dataset contains information about human research subjects. Because there is potential to identify individual participants and disclose personal information, either alone or in combination with other datasets, individual level data are not appropriate to post for public access. Restricted access may be granted to authorized persons by contacting the party listed. It can be accessed through the following means: Human health data are not available publicly. EQI data are available at: https://edg.epa.gov/data/Public/ORD/NHEERL/EQI. Format: Data are stored as csv files. This dataset is associated with the following publication: Jagai, J., A. Krajewski, S. Shaikh, D. Lobdell, and R. Sargis. Association between environmental quality and diabetes in the U.S.A.. Journal of Diabetes Investigation. John Wiley & Sons, Inc., Hoboken, NJ, USA, 11(2): 315-324, (2020).

Diabetes Mellitus death rates by county, all races (includes Hispanic/Latino), all sexes, all ages, 2019-2023. Death data were provided by the National Vital Statistics System. Death rates (deaths per 100,000 population per year) are age-adjusted to the 2000 US standard population (20 age groups: <1, 1-4, 5-9, ... , 80-84, 85-89, 90+). Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by the National Cancer Institute. The US Population Data File is used for mortality data. The Average Annual Percent Change is based onthe APCs calculated by the Joinpoint Regression Program (Version 4.9.0.0). Due to data availability issues, the time period used in the calculation of the joinpoint regression model may differ for selected counties. Counties with a (3) after their name may have their joinpoint regresssion model calculated using a different time period due to data availability issues.

These data represent the predicted (modeled) prevalence of Diabetes among adults (Age 18+) for each census tract in Colorado. Diabetes is defined as ever being diagnosed with Diabetes by a doctor, nurse, or other health professional, and this definition does not include gestational, borderline, or pre-diabetes.The estimate for each census tract represents an average that was derived from multiple years of Colorado Behavioral Risk Factor Surveillance System data (2014-2017).CDPHE used a model-based approach to measure the relationship between age, race, gender, poverty, education, location and health conditions or risk behavior indicators and applied this relationship to predict the number of persons' who have the health conditions or risk behavior for each census tract in Colorado. We then applied these probabilities, based on demographic stratification, to the 2013-2017 American Community Survey population estimates and determined the percentage of adults with the health conditions or risk behavior for each census tract in Colorado.The estimates are based on statistical models and are not direct survey estimates. Using the best available data, CDPHE was able to model census tract estimates based on demographic data and background knowledge about the distribution of specific health conditions and risk behaviors.The estimates are displayed in both the map and data table using point estimate values for each census tract and displayed using a Quintile range. The high and low value for each color on the map is calculated based on dividing the total number of census tracts in Colorado (1249) into five groups based on the total range of estimates for all Colorado census tracts. Each Quintile range represents roughly 20% of the census tracts in Colorado. No estimates are provided for census tracts with a known population of less than 50. These census tracts are displayed in the map as "No Est, Pop < 50."No estimates are provided for 7 census tracts with a known population of less than 50 or for the 2 census tracts that exclusively contain a federal correctional institution as 100% of their population. These 9 census tracts are displayed in the map as "No Estimate."

Context

The most prevalent condition in the study is obesity, affecting just over 30 percent of Americans and it followed by diabetes which has a national prevalence of 11.2 percent. Chronic obstructive pulmonary disease (COPD) and cardiovascular disease have a prevalence of just under 7 percent while chronic kidney disease is at approximately 3 percent. The CDC stated that "while the estimated number of persons with any underlying medical condition was higher in population-dense metropolitan areas, overall prevalence was higher in rural nonmetropolitan areas". It also added that "the counties with the highest prevalences of any condition were concentrated in Southeastern states, particularly in Alabama, Arkansas, Kentucky, Louisiana, Mississippi, Tennessee, and West Virginia, as well as some counties in Oklahoma, South Dakota, Texas, and northern Michigan, among others".

https://www.statista.com/chart/22365/prevalence-of-underlying-conditions-in-us-adults/

Content

Several studies have found that the risk of contracting severe Covid-19 that can result in hospitalization, ICU admission, mechanical ventilation or death increases with age as well as the presence of underlying health conditions. In the United States, the Centers for Disease Control and Prevention (CDC) recently released a study showing that a considerable share of the American population has some form of underlying health issue, placing them at risk from severe forms of the virus. The study's findings are based on the 2018 Behavioural Risk Factor Surveillance System (BRFSS) and U.S. Census population data and it determined that 40.7 percent of U.S. adults (aged 18 and over) have a pre-existing health condition.

Acknowledgements

Niall McCarthy, Data Journalist https://www.statista.com/chart/22365/prevalence-of-underlying-conditions-in-us-adults/

Inspiration

Covid-19

The share of the population with overweight in the United States was forecast to continuously increase between 2024 and 2029 by in total 1.6 percentage points. After the fifteenth consecutive increasing year, the overweight population share is estimated to reach 77.43 percent and therefore a new peak in 2029. Notably, the share of the population with overweight of was continuously increasing over the past years.Overweight is defined as a body mass index (BMI) of more than 25.The shown data are an excerpt of Statista's Key Market Indicators (KMI). The KMI are a collection of primary and secondary indicators on the macro-economic, demographic and technological environment in up to 150 countries and regions worldwide. All indicators are sourced from international and national statistical offices, trade associations and the trade press and they are processed to generate comparable data sets (see supplementary notes under details for more information).Find more key insights for the share of the population with overweight in countries like Canada and Mexico.

The size of the North America Self-monitoring Blood Glucose Market was valued at USD 8.10 Million in 2023 and is projected to reach USD 12.99 Million by 2032, with an expected CAGR of 6.98% during the forecast period. Recent developments include: May 2023: LifeScan announced positive data from a study of real-world evidence supporting its Bluetooth-connected blood glucose meter. Evidence from more than 55,000 people with diabetes demonstrated sustained improvements in readings in range. The analysis focuses on changes over 180 days. LifeScan published results in the peer-reviewed journal Diabetes Therapy. The company’s OneTouch Bluetooth-connected blood glucose meter and mobile diabetes app provide simplicity, accuracy, and trust., January 2023: LifeScan announced that the peer-reviewed Journal of Diabetes Science and Technology published Improved Glycemic Control Using a Bluetooth-Connected Blood Glucose Meter and a Mobile Diabetes App: Real-World Evidence from Over 144,000 People With Diabetes, detailing results from a retrospective analysis of real-world data from over 144,000 people with diabetes is one of the largest combined blood glucose meter and mobile diabetes app datasets ever published.. Key drivers for this market are: Rising Prevalence of Cancer Worldwide, Technological Advancements in Diagnostic Testing; Increasing Demand for Point-of-care Treatment. Potential restraints include: High Cost of Molecular Diagnostic Tests, Lack of Skilled Workforce and Stringent Regulatory Framework. Notable trends are: Blood Glucose Test Strips Held the Largest Market Share in Current Year.

The goal is to predict the rate of heart disease (per 100,000 individuals) across the United States at the county-level from other socioeconomic indicators. The data is compiled from a wide range of sources and made publicly available by the United States Department of Agriculture Economic Research Service (USDA ERS).

There are 33 variables in this dataset. Each row in the dataset represents a United States county, and the dataset we are working with covers two particular years, denoted a, and b We don't provide a unique identifier for an individual county, just a row_id for each row.

The variables in the dataset have names that of the form category_variable, where category is the high level category of the variable (e.g. econ or health). variable is what the specific column contains.

We're trying to predict the variable heart_disease_mortality_per_100k (a positive integer) for each row of the test data set.

Columns

area — information about the county

area_rucc — Rural-Urban Continuum Codes "form a classification scheme that distinguishes metropolitan counties by the population size of their metro area, and nonmetropolitan counties by degree of urbanization and adjacency to a metro area. The official Office of Management and Budget (OMB) metro and nonmetro categories have been subdivided into three metro and six nonmetro categories. Each county in the U.S. is assigned one of the 9 codes." (USDA Economic Research Service, https://www.ers.usda.gov/data-products/rural-urban-continuum-codes/)

area_urban_influence — Urban Influence Codes "form a classification scheme that distinguishes metropolitan counties by population size of their metro area, and nonmetropolitan counties by size of the largest city or town and proximity to metro and micropolitan areas." (USDA Economic Research Service, https://www.ers.usda.gov/data-products/urban-influence-codes/)

econ — economic indicators

econ_economic_typology — County Typology Codes "classify all U.S. counties according to six mutually exclusive categories of economic dependence and six overlapping categories of policy-relevant themes. The economic dependence types include farming, mining, manufacturing, Federal/State government, recreation, and nonspecialized counties. The policy-relevant types include low education, low employment, persistent poverty, persistent child poverty, population loss, and retirement destination." (USDA Economic Research Service, https://www.ers.usda.gov/data-products/county-typology-codes.aspx)

econ_pct_civilian_labor — Civilian labor force, annual average, as percent of population (Bureau of Labor Statistics, http://www.bls.gov/lau/)

econ_pct_unemployment — Unemployment, annual average, as percent of population (Bureau of Labor Statistics, http://www.bls.gov/lau/)

econ_pct_uninsured_adults — Percent of adults without health insurance (Bureau of Labor Statistics, http://www.bls.gov/lau/) econ_pct_uninsured_children — Percent of children without health insurance (Bureau of Labor Statistics, http://www.bls.gov/lau/)

health — health indicators

health_pct_adult_obesity — Percent of adults who meet clinical definition of obese (National Center for Chronic Disease Prevention and Health Promotion)

health_pct_adult_smoking — Percent of adults who smoke (Behavioral Risk Factor Surveillance System)

health_pct_diabetes — Percent of population with diabetes (National Center for Chronic Disease Prevention and Health Promotion, Division of Diabetes Translation)

health_pct_low_birthweight — Percent of babies born with low birth weight (National Center for Health Statistics)

health_pct_excessive_drinking — Percent of adult population that engages in excessive consumption of alcohol (Behavioral Risk Factor Surveillance System, )

health_pct_physical_inacticity — Percent of adult population that is physically inactive (National Center for Chronic Disease Prevention and Health Promotion)

health_air_pollution_particulate_matter — Fine particulate matter in µg/m³ (CDC WONDER, https://wonder.cdc.gov/wonder/help/pm.html)

health_homicides_per_100k — Deaths by homicide per 100,000 population (National Center for Health Statistics)

health_motor_vehicle_crash_deaths_per_100k — Deaths by motor vehicle crash per 100,000 population (National Center for Health Statistics)

health_pop_per_dentist — Population per dentist (HRSA Area Resource File)

health_pop_per_primary_care_physician — Population per Primary Care Physician (HRSA Area Resource File)

demo — demographics information

demo_pct_female — Percent of population that is female (US Census Population Estimates)

demo_pct_below_18_years_of_age — Percent of population that is below 18 years of age (US Census Population Estimates)

demo_pct_aged_65_years_and_older — Percent of population that is aged 65 years or older (US Census Population Estimates)

dem...

The North American self-monitoring blood glucose (SMBG) market, valued at $8.10 billion in 2025, is projected to experience robust growth, driven by the increasing prevalence of diabetes and the rising geriatric population. The market's Compound Annual Growth Rate (CAGR) of 6.98% from 2019 to 2025 indicates a consistent upward trend. Key drivers include advancements in SMBG device technology, such as the development of more accurate, user-friendly, and cost-effective glucometers and lancets. Furthermore, increased awareness of diabetes management and the growing adoption of remote patient monitoring contribute significantly to market expansion. While data for individual countries within North America (United States, Canada, and Rest of North America) are not provided, we can infer that the United States likely holds the largest market share given its substantial population and higher prevalence of diabetes compared to Canada. The Rest of North America segment will likely exhibit moderate growth, reflecting the combined market dynamics of smaller countries in the region. Market restraints may include the potential for reimbursement challenges and the emergence of alternative glucose monitoring technologies, such as continuous glucose monitors (CGMs). However, the overall market outlook remains positive, fueled by the persistent need for effective diabetes management. Major players like Abbott, Roche, and LifeScan continue to innovate and compete, further shaping the market landscape. The forecast period (2025-2033) promises continued growth driven by technological advancements and an aging population requiring consistent blood glucose monitoring. The competitive landscape is characterized by established players like Abbott, Roche, and LifeScan, along with other significant contributors like Arkray, Ascensia, and Agamatrix. These companies are continuously striving for innovation to maintain their market share. This involves introducing technologically advanced devices, improving user experience, and developing more comprehensive diabetes management solutions. The increasing demand for accurate, convenient, and affordable SMBG devices, coupled with the growing awareness of diabetes self-management, will drive further market expansion. The incorporation of data analytics and connectivity features in SMBG devices also plays a crucial role in fostering better diabetes management and patient outcomes, thereby bolstering the market's growth trajectory. The focus on improving patient outcomes and reducing healthcare costs will likely shape future market developments, attracting further investments and technological advancements within the sector. Recent developments include: May 2023: LifeScan announced positive data from a study of real-world evidence supporting its Bluetooth-connected blood glucose meter. Evidence from more than 55,000 people with diabetes demonstrated sustained improvements in readings in range. The analysis focuses on changes over 180 days. LifeScan published results in the peer-reviewed journal Diabetes Therapy. The company’s OneTouch Bluetooth-connected blood glucose meter and mobile diabetes app provide simplicity, accuracy, and trust., January 2023: LifeScan announced that the peer-reviewed Journal of Diabetes Science and Technology published Improved Glycemic Control Using a Bluetooth-Connected Blood Glucose Meter and a Mobile Diabetes App: Real-World Evidence from Over 144,000 People With Diabetes, detailing results from a retrospective analysis of real-world data from over 144,000 people with diabetes is one of the largest combined blood glucose meter and mobile diabetes app datasets ever published.. Notable trends are: Blood Glucose Test Strips Held the Largest Market Share in Current Year.

This table contains data on the percent of population aged 16 years or older whose commute to work is 10 or more minutes/day by walking or biking for California, its regions, counties, and cities/towns. Data is from the U.S. Census Bureau, American Community Survey, and from the U.S. Department of Transportation, Federal Highway Administration, and National Household Travel Survey. The table is part of a series of indicators in the Healthy Communities Data and Indicators Project of the Office of Health Equity. Active modes of transport, bicycling and walking alone and in combination with public transit, offer opportunities to incorporate physical activity into the daily routine. Physical activity is associated with lowering rates of heart disease and stroke, diabetes, colon and breast cancer, dementia and depression. Automobile commuting is associated with health hazards, such as air pollution, motor vehicle crashes, pedestrian injuries and fatalities, and sedentary lifestyles. Consequently the transition from automobile-focused transport to public and active transport offers environmental health benefits, including reductions in air pollution, greenhouse gases and noise pollution, and may lead to greater overall safety in transportation. More information about the data table and a data dictionary can be found in the About/Attachments section.

Dataset name: Diabetes 130-US hospitals for years 1999-2008 Data Set

Background: Diabetes Mellitus (DM) is a chronic disease where the blood has high sugar level. It can occur when the pancreas does not produce enough insulin, or when the body cannot effectively use the insulin it produces (WHO). Diabetes is a progressive disease that can lead to a significant number of health complications and profoundly reduce the quality of life. While many diabetic patients manage the health complication with diet and exercise, some require medications to control blood glucose level. As published by a research article named “The relationship between diabetes mellitus and 30-day readmission rates”, it is estimated that 9.3% of the population in the United States have diabetes mellitus (DM), 28% of which are undiagnosed. In recent years, government agencies and healthcare systems have increasingly focused on 30-day readmission rates to determine the complexity of their patient populations and to improve quality. Thirty-day readmission rates for hospitalized patients with DM are reported to be between 14.4 and 22.7%, much higher than the rate for all hospitalized patients (8.5–13.5%).

Problem Statement: To identify the factors that lead to the high readmission rate of diabetic patients within 30 days post discharge and correspondingly to predict the high-risk diabetic-patients who are most likely to get readmitted within 30 days so that the quality of care can be improved along with improved patient’s experience, health of the population and reduce costs by lowering readmission rates. Also, to identify the medicines that are the most effective in treating diabetes.

Impact on business: Hospital readmission is an important contributor to total medical expenditures and is an emerging indicator of quality of care. Diabetes, similar to other chronic medical conditions, is associated with increased risk of hospital readmission. As mentioned in the article “Correction to: Hospital Readmission of Patients with Diabetes”, hospital readmission is a high-priority health care quality measure and target for cost reduction, particularly within 30 days of discharge. The burden of diabetes among hospitalized patients is substantial, growing, and costly, and readmissions contribute a significant portion of this burden. Reducing readmission rates among patients with diabetes has the potential to greatly reduce health care costs while simultaneously improving care. Our aim is to provide some insights into the risk factors for readmission and also to identify the medicines that are the most effective in treating diabetes.

Variable identification: 1. Independent variables (49): encounter_id, patient_nbr, race, gender, age, weight, admission_type_id, discharge_disposition_id, admission_source_id, time_in_hospital, payer_code, medical_specialty, num_lab_procedures, num_procedures, num_medications, number_outpatient, number_emergency, number_inpatient, diag_1, diag_2, diag_3, number_diagnoses, max_glu_serum, A1Cresult, metformin, repaglinide, nateglinide, chlorpropamide, glimepiride, acetohexamide, glipizide, glyburide, tolbutamide, pioglitazone, rosiglitazone, acarbose, miglitol, troglitazone, tolazamide, examide, citoglipton, insulin, glyburide-metformin, glipizide-metformin, glimepiride-pioglitazone, metformin-rosiglitazone, metformin-pioglitazone, change, diabetesMed. ***2. Dependent variable (1)**:* readmitted (Categorical)

Extra Info: Our dataset consists of hospital admissions of length between one and 14 days that did not result in a patient’s death. Each encounter corresponds to a patient diagnosed with diabetes, although the primary diagnosis may be different. During each of the analyzed encounters, lab tests were ordered and medication was administered.

The global Diabetes Care Devices market, valued at approximately $XX million in 2025, is projected to experience robust growth, driven by rising diabetes prevalence globally, an aging population, and increasing adoption of advanced technologies like continuous glucose monitoring (CGM). The market's Compound Annual Growth Rate (CAGR) of 5.10% from 2025 to 2033 indicates a significant expansion, with substantial opportunities across various segments. Self-monitoring blood glucose (SMBG) devices, including glucometers, test strips, and lancets, continue to dominate the market due to their widespread accessibility and affordability. However, the CGM segment is witnessing exponential growth, fueled by its enhanced accuracy, convenience, and ability to provide real-time glucose data, leading to improved diabetes management. The increasing demand for insulin delivery devices, such as insulin pumps, syringes, pens, and jet injectors, also contributes significantly to market expansion. Technological advancements, including the development of integrated devices and improved sensor technologies, are further propelling market growth. The market is geographically diverse, with North America and Europe currently holding the largest market share due to high diabetes prevalence and developed healthcare infrastructure. However, Asia Pacific is emerging as a high-growth region, driven by rising disposable incomes and increasing healthcare awareness. Market restraints include the high cost of advanced devices, particularly CGMs and insulin pumps, which can limit accessibility in low- and middle-income countries. Furthermore, the need for regular calibration and potential inaccuracies associated with some devices present challenges. Despite these restraints, the continuous development of more affordable and user-friendly devices, coupled with supportive government initiatives and rising awareness campaigns, are expected to mitigate these challenges and drive market expansion throughout the forecast period. Key players in the market, including Abbott, Roche, Dexcom, Medtronic, and Novo Nordisk, are heavily invested in research and development, further fueling innovation and market competition. This competitive landscape will continue to shape the market dynamics, leading to advancements in technology and more accessible and affordable diabetes care solutions. Recent developments include: March 2023: Abbott announced that the U.S. Food and Drug Administration cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated continuous glucose monitoring system sensors for integration with automated insulin delivery (AID) systems. Abbott modified the sensors to enable integration with AID systems., January 2023: LifeScan announced that the peer-reviewed Journal of Diabetes Science and Technology published Improved Glycemic Control Using a Bluetooth Connected Blood Glucose Meter and a Mobile Diabetes App: Real-World Evidence From Over 144,000 People With Diabetes, detailing results from a retrospective analysis of real-world data from over 144,000 people with diabetes - one of the largest combined blood glucose meter and mobile diabetes app datasets ever published.. Notable trends are: The continuous glucose monitoring segment is expected to witness a healthy growth rate over the forecast period.

Rank, number of deaths, percentage of deaths, and age-specific mortality rates for the leading causes of death, by age group and sex, 2000 to most recent year.

The Latin American diabetes care devices market, valued at approximately $XX million in 2025, is projected to experience robust growth, exhibiting a compound annual growth rate (CAGR) of 5.64% from 2025 to 2033. This expansion is fueled by several key factors. The rising prevalence of diabetes across Brazil, Mexico, and the rest of Latin America, coupled with increasing awareness of effective disease management, is driving demand for both self-monitoring and management devices. Technological advancements, such as the introduction of more user-friendly continuous glucose monitoring (CGM) systems and improved insulin delivery technologies like insulin pumps, are further stimulating market growth. Government initiatives promoting diabetes awareness and affordable access to healthcare are also contributing positively. However, high costs associated with advanced devices, limited healthcare infrastructure in certain regions, and a lack of patient education in some areas pose challenges to market penetration. The market is segmented by device type (self-monitoring blood glucose devices – including glucometers, test strips, and lancets; CGMs – encompassing sensors, receivers, and transmitters; and management devices like insulin pumps, syringes, pens, and jet injectors) and geography (Brazil, Mexico, and the rest of Latin America). Brazil and Mexico are expected to be the largest markets due to their significant populations and relatively higher prevalence of diabetes. The competitive landscape is characterized by the presence of major global players like Abbott, Dexcom, Medtronic, and Roche, alongside several regional players. The future of the Latin American diabetes care devices market appears bright, although further growth hinges on several factors. Addressing affordability concerns through government subsidies and insurance coverage is critical. Furthermore, improving healthcare infrastructure and expanding patient education programs will be crucial to maximizing market potential. Strategic partnerships between manufacturers, healthcare providers, and government bodies can facilitate wider adoption of advanced technologies. Specific focus should be placed on improving access to CGM technology, which offers significant improvements in diabetes management compared to traditional self-monitoring methods. The growing adoption of telehealth and remote monitoring will also contribute to the market's future trajectory. Competitive strategies will likely focus on innovation, product differentiation, and expanding distribution networks to reach diverse patient populations across the region. Recent developments include: January 2023: LifeScan announced that the peer-reviewed Journal of Diabetes Science and Technology published Improved Glycemic Control Using a Bluetooth Connected Blood Glucose Meter and a Mobile Diabetes App: Real-World Evidence From Over 144,000 People With Diabetes, detailing results from a retrospective analysis of real-world data from over 144,000 people with diabetes - one of the largest combined blood glucose meter and mobile diabetes app datasets ever published., October 2022: Becton, Dickinson, and Company and Biocorp announced that they had signed an agreement to use connected technology to track adherence to self-administered drug therapies, like biologics. To support biopharmaceutical companies in their efforts to improve the adherence and outcomes of injectable drugs, the two companies will integrate Biocorp's Injay technology-a solution designed to capture and transmit injection events using Near Field Communication technology to the BD UltraSafe Plus Passive Needle Guard used with pre-fillable syringes.. Notable trends are: The Continuous Glucose Monitoring Segment is expected to witness the highest growth rate over the forecast period.

Proportion of children aged 10 to 11 years classified as living with obesity. For population monitoring purposes, a child’s body mass index (BMI) is classed as overweight or obese where it is on or above the 85th centile or 95th centile, respectively, based on the British 1990 (UK90) growth reference data. The population monitoring cut offs for overweight and obesity are lower than the clinical cut offs (91st and 98th centiles for overweight and obesity) used to assess individual children; this is to capture children in the population in the clinical overweight or obesity BMI categories and those who are at high risk of moving into the clinical overweight or clinical obesity categories. This helps ensure that adequate services are planned and delivered for the whole population.

Rationale There is concern about the rise of childhood obesity and the implications of obesity persisting into adulthood. The risk of obesity in adulthood and risk of future obesity-related ill health are greater as children get older. Studies tracking child obesity into adulthood have found that the probability of children who are overweight or living with obesity becoming overweight or obese adults increases with age[1,2,3]. The health consequences of childhood obesity include: increased blood lipids, glucose intolerance, Type 2 diabetes, hypertension, increases in liver enzymes associated with fatty liver, exacerbation of conditions such as asthma and psychological problems such as social isolation, low self-esteem, teasing and bullying.

It is important to look at the prevalence of weight status across all weight/BMI categories to understand the whole picture and the movement of the population between categories over time.

The National Institute of Health and Clinical Excellence have produced guidelines to tackle obesity in adults and children - http://guidance.nice.org.uk/CG43.

1 Guo SS, Chumlea WC. Tracking of body mass index in children in relation to overweight in adulthood. The American Journal of Clinical Nutrition 1999;70(suppl): 145S-8S.

2 Serdula MK, Ivery D, Coates RJ, Freedman DS, Williamson DF, Byers T. Do obese children become obese adults? A review of the literature. Preventative Medicine 1993;22:167-77.

3 Starc G, Strel J. Tracking excess weight and obesity from childhood to young adulthood: a 12-year prospective cohort study in Slovenia. Public Health Nutrition 2011;14:49-55.

Definition of numerator Number of children in year 6 (aged 10 to 11 years) with a valid height and weight measured by the NCMP with a BMI classified as living with obesity or severe obesity (BMI on or above 95th centile of the UK90 growth reference).

Definition of denominator Number of children in year 6 (aged 10 to 11 years) with a valid height and weight measured by the NCMP.

Caveats Data for local authorities may not match that published by NHS England which are based on the local authority of the school attended by the child or based on the local authority that submitted the data. There is a strong correlation between deprivation and child obesity prevalence and users of these data may wish to examine the pattern in their local area. Users may wish to produce thematic maps and charts showing local child obesity prevalence. When presenting data in charts or maps it is important, where possible, to consider the confidence intervals (CIs) around the figures. This analysis supersedes previously published data for small area geographies and historically published data should not be compared to the latest publication. Estimated data published in this fingertips tool is not comparable with previously published data due to changes in methods over the different years of production. These methods changes include; moving from estimated numbers at ward level to actual numbers; revision of geographical boundaries (including ward boundary changes and conversion from 2001 MSOA boundaries to 2011 boundaries); disclosure control methodology changes. The most recently published data applies the same methods across all years of data. There is the potential for error in the collection, collation and interpretation of the data (bias may be introduced due to poor response rates and selective opt out of children with a high BMI for age/sex which it is not possible to control for). There is not a good measure of response bias and the degree of selective opt out, but participation rates (the proportion of eligible school children who were measured) may provide a reasonable proxy; the higher the participation rate, the less chance there is for selective opt out, though this is not a perfect method of assessment. Participation rates for each local authority are available in the https://fingertips.phe.org.uk/profile/national-child-measurement-programme/data#page/4/gid/8000022/ of this profile.

This data set provides eight feature classes. The base feature class is called CensusTracts_tr and isn't generalized. The weighted centroids feature class is called CensusTracts_tr_cent. The centroids are weighted by the U.S. Block Centroids population distribution. Use the weighted centroids in report aggregation and spatial overlay operations. The CensusTracts_tr and CensusTracts_tr_cent feature classes contain all the attributes. There are six generalized boundaries feature classes and called: CensusTracts_tr_gen2, CensusTracts_tr_gen3, CensusTracts_tr_gen4, CensusTracts_tr_gen5, CensusTracts_tr_gen6 and CensusTracts_tr_gen7. These generalized features classes are provided to be used in mapping applications where very detailed feature classes can slow down performance.

This dataset provides a comprehensive exploration of global sugar consumption patterns over six decades, synthesizing economic, agricultural, and public health data to uncover the drivers and consequences of rising sugar intake. Spanning 1960–2023, country-year entries for 200+ nations, with 25+ variables such as:

Economic Indicators: GDP per capita, urbanization rates, and retail sugar prices.

Agricultural Data: Sugarcane/beet production yields, climate suitability, and trade dynamics (imports/exports).

Health Metrics: Diabetes prevalence, obesity rates, and daily sugar intake.

Policy Interventions: Sugar taxes, subsidies, and national education campaigns.

Key Features: Temporal & Geographic Depth: Track regional shifts (e.g., Southeast Asia’s sugarcane boom, North America’s HFCS dominance) and long-term trends (e.g., 300% rise in per capita intake in developing nations post-2000).

Health-Economic Correlations: Model relationships between sugar consumption, GDP growth, and non-communicable diseases (e.g., +1kg/year sugar intake → +0.5% obesity rate).

Policy Impact Analysis: Evaluate the effectiveness of interventions like sugar taxes (5–15% consumption decline in adopters) or subsidies.

Synthetic Realism: Data mimics real-world sources (e.g., FAO, WHO) with logical constraints (e.g., Total_Sugar_Consumption = Population × Per_Capita).

Applications: Public Health: Identify nations at risk for diabetes/obesity epidemics.

Economic Policy: Analyze trade dependencies or subsidy impacts.

Agricultural Planning: Optimize crop yields based on climate trends.

Machine Learning: Predict future consumption or simulate policy outcomes.

DESCRIPTION This table contains data on the percent of residents aged 16 years and older mode of transportation to work for ...

SUMMARY This table contains data on the percent of residents aged 16 years and older mode of transportation to work for California, its regions, counties, cities/towns, and census tracts. Data is from the U.S. Census Bureau, Decennial Census and American Community Survey. The table is part of a series of indicators in the Healthy Communities Data and Indicators Project of the Office of Health Equity. Commute trips to work represent 19% of travel miles in the United States. The predominant mode – the automobile - offers extraordinary personal mobility and independence, but it is also associated with health hazards, such as air pollution, motor vehicle crashes, pedestrian injuries and fatalities, and sedentary lifestyles. Automobile commuting has been linked to stress-related health problems. Active modes of transport – bicycling and walking alone and in combination with public transit – offer opportunities for physical activity, which is associated with lowering rates of heart disease and stroke, diabetes, colon and breast cancer, dementia and depression. Risk of injury and death in collisions are higher in urban areas with more concentrated vehicle and pedestrian activity. Bus and rail passengers have a lower risk of injury in collisions than motorcyclists, pedestrians, and bicyclists. Minority communities bear a disproportionate share of pedestrian-car fatalities; Native American male pedestrians experience four times the death rate Whites or Asian pedestrians, and African-Americans and Latinos experience twice the rate as Whites or Asians. More information about the data table and a data dictionary can be found in the About/Attachments section.

ind_id - Indicator ID ind_definition - Definition of indicator in plain language reportyear - Year that the indicator was reported race_eth_code - numeric code for a race/ethnicity group race_eth_name - Name of race/ethnic group geotype - Type of geographic unit geotypevalue - Value of geographic unit geoname - Name of a geographic unit county_name - Name of county that geotype is in county_fips - FIPS code of the county that geotype is in region_name - MPO-based region name; see MPO_County list tab region_code - MPO-based region code; see MPO_County list tab mode - Mode of transportation short name mode_name - Mode of transportation long name pop_total - denominator pop_mode - numerator percent - Percent of Residents Mode of Transportation to Work,
Population Aged 16 Years and Older LL_95CI_percent - The lower limit of 95% confidence interval UL_95CI_percent - The lower limit of 95% confidence interval percent_se - Standard error of the percent mode of transportation percent_rse - Relative standard error (se/value) expressed as a percent CA_decile - California decile CA_RR - Rate ratio to California rate version - Date/time stamp of a version of data

Energy and nutrient intakes from all snacks and the percent of the day’s intakes of energy and nutrients obtained from snacks in people aged 30+ years with different diabetes status.